GlassScriptPhysician profile
Nazal Obaid
NPI 1891797064
$16,449.32
in general payments reported to CMS, 2019-2025
51 companies · $1,727 in 2025
The $1,727 reported for 2025 was more than what 81% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,278 · 2020: $764 · 2021: $1,924 · 2022: $2,061 · 2023: $1,917 · 2024: $3,779 · 2025: $1,727.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,407 · Travel and Lodging: $1,015.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,407.42 |
| Travel and Lodging | $1,015.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,225.74 | 2019-2025 | |
| W. L. Gore & Associates, INC. | $1,923.43 | 2022-2025 | Gore Viabahn Vbx Balloon Expandable Endo, Gore Viabahn Endoprosthesis, Gore Excluder Thoracoabdominal Branch Endoprosthesis |
| Philips North America LLC | $1,049.13 | 2019 | |
| Merck Sharp & Dohme LLC | $894.67 | 2021-2025 | Verquvo, Belsomra |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $813.78 | 2019-2025 | Lifevest |
| Ekos Corporation | $730.52 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $689.33 | 2019-2025 | Jardiance |
| Medtronic, INC. | $656.67 | 2021-2025 | Abre, In.Pact Admiral, Endurant Iis |
| Abiomed | $653.82 | 2019-2025 | Impella |
| Boston Scientific Corporation | $626.97 | 2019-2024 | Watchman Flx |
| Esperion Therapeutics, INC. | $605.26 | 2021-2024 | Nexletol |
| Janssen Pharmaceuticals, INC | $569.49 | 2019-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $553.32 | 2019-2025 | Farxiga, Brilinta, Wainua |
| E.R. Squibb & Sons, L.L.C. | $468.11 | 2019-2025 | Camzyos, Eliquis |
| Abbott Laboratories | $439.38 | 2019-2025 | Esprit |
Show all 51 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $438.86 | 2019-2025 | Repatha, Repatha |
| Sanofi-Aventis U.S. LLC | $362.41 | 2019-2022 | |
| Pfizer INC. | $229.35 | 2019-2025 | |
| Chiesi USA, INC. | $224.86 | 2020-2023 | Cleviprex, Kengreal |
| Penumbra, INC. | $222.13 | 2024 | Indigo System |
| Endologix LLC | $217.58 | 2021-2023 | Ovation Ix Iliac Stent Graft |
| Biosense Webster, INC. | $159.81 | 2019 | |
| Vifor Pharma, INC. | $155.55 | 2019-2021 | |
| Silk Road Medical, INC. | $150.00 | 2024 | Enroute Transcarotid Neuroprotection System, Enroute Enflate Transcarotid Rx Balloon Dilatation Catheter, Enroute Transcarotid Stent |
| Actelion Pharmaceuticals US, INC. | $147.38 | 2022-2024 | Uptravi, Opsumit |
| Bard Peripheral Vascular, INC. | $139.05 | 2019 | |
| Novo Nordisk INC | $111.48 | 2023-2025 | Wegovy, Ozempic |
| Stryker Corporation | $101.80 | 2025 | Artix Mt |
| Cardiovascular Systems INC. | $101.40 | 2020-2022 | |
| Kestra Medical Technology Services, INC. | $78.49 | 2022 | |
| Amarin Pharma, INC. | $70.41 | 2019-2022 | |
| Scpharmaceuticals INC. | $53.99 | 2024 | |
| Kiniksa Pharmaceuticals, LTD. | $47.50 | 2021 | |
| Shockwave Medical, INC | $47.02 | 2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Lexicon Pharmaceuticals, INC. | $46.98 | 2024 | |
| Lundbeck LLC | $46.16 | 2019-2020 | |
| Medtronic Vascular, INC. | $39.69 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $38.12 | 2023-2025 | |
| Cardiva Medical, INC. | $36.04 | 2023 | Cardiva Vascade Mvp Vvcs 6-12f, Cardiva Vascade 6/7f Vcs |
| Edwards Lifesciences Corporation | $34.15 | 2019-2025 | Sapien 3 Ultra Resilia |
| Kiniksa Pharmaceuticals International, Plc | $32.76 | 2024 | Arcalyst |
| Kowa Pharmaceuticals America, INC. | $30.15 | 2019 | |
| Teleflex LLC | $29.42 | 2025 | Guideliner |
| Arbor Pharmaceuticals, INC. | $26.43 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $22.79 | 2019 | |
| Lilly USA, LLC | $21.62 | 2025 | Zepbound, Mounjaro |
| Atricure, INC. | $21.59 | 2023 | |
| Sanofi Pasteur INC. | $19.39 | 2023 | |
| Glaxosmithkline, LLC. | $16.52 | 2025 | Shingrix |
| Gilead Sciences, INC. | $15.33 | 2019 | |
| Impulse Dynamics (USA) INC. | $13.49 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nazal Obaid listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.